<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83491">
  <stage>Registered</stage>
  <submitdate>6/01/2009</submitdate>
  <approvaldate>11/02/2009</approvaldate>
  <actrnumber>ACTRN12609000096257</actrnumber>
  <trial_identification>
    <studytitle>Assessment of the potential of nebulised frusemide to relieve dyspnoea in people with advanced heart failure</studytitle>
    <scientifictitle>Assessment of the potential of nebulised frusemide to relieve dyspnoea in people with advanced heart failure</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>St Vincent's Hospital Reference number H06/074</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose administration of nebulised frusemide 40 mg (in 4 ml of diluent) to patients with chronic heart failure undergoing clinically-indicated right heart catheterisation. Frusemide/matching placebo is delivered as a single dose via a nebuliser immediately during right heart catheterisation immediately after completion of baseline haemodynamic measurements</interventions>
    <comparator>Placebo consists of 4 ml Normal Saline also delivered as a single dose via a nebulised solution</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Acute haemodynamic changes over one hour post drug administration. The primary endpoint is the change in pulmonary artery wedge pressure (mmHG) measured directly with a Swan-Ganz catheter over one hour after administration of study drug.</outcome>
      <timepoint>Baseline (before study drug administration), then 15, 30, 45, 60 minutes after study drug administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Dyspnoea Score - assessed by visual analogue scale (0-10)</outcome>
      <timepoint>Baseline (before study drug administration), then 15, 30, 45, 60 minutes after study drug administration</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Chronic stable heart failure
New York  Heart Association Class 2-3</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Acute decompensated heart failure
NYHA Class 1 or 4
Inability to provide informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomisation undertaken by Clinical Trials Pharmacist at St Vincent's Hospital, who dispensed trial medication as unmarked solution for administration. All investigators and patients remained blinded to treatment (active versus placebo).</concealment>
    <sequence>Simple randomisation by using a randomisation table created by a computer software (i.e., computerised sequence generation)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>28/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>32</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital</primarysponsorname>
    <primarysponsoraddress>Victoria St
Darlinghurst
NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Patricia Davidson</othercollaboratorname>
      <othercollaboratoraddress>Centre for Cardiovascular And Chronic Care
Curtin University of Technology
38 Regent St, Chippendale
Sydney, NSW, 2008</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Dyspnea is a burdensome symptom for individuals with heart failure (HF) and is responsible for high rates of hospitalization. Observational data, predominately in respiratory and cancer patients, suggest that nebulised furosemide may be useful for the symptomatic management of dyspnea. This evidence to date remains inconclusive and there have been no reports of the use of inhaled frusemide in HF. The aim of this study is to assess the impact of nebulised frusemide on the haemodynamic measures of heart function and on the symptom of dyspnoea in a population of patients with stable chronic heart failure</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital</ethicname>
      <ethicaddress>390 Victoria St
Darlinghurst
NSW 2010</ethicaddress>
      <ethicapprovaldate>28/08/2006</ethicapprovaldate>
      <hrec>H06/074</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Phillip Newton</name>
      <address>Centre for Cardiovascular And Chronic Care
Curtin University of Technology
38 Regent St, Chippendale
Sydney, NSW, 2008</address>
      <phone>+61 2 8399 7832</phone>
      <fax>+61 2 8399 7834</fax>
      <email>p.newton@curtin.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Phillip Newton</name>
      <address>Centre for Cardiovascular And Chronic Care
Curtin University of Technology
38 Regent St, Chippendale
Sydney, NSW, 2008</address>
      <phone>+61 2 8399 7832</phone>
      <fax>+61 2 8399 7834</fax>
      <email>p.newton@curtin.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Phillip Newton</name>
      <address>Centre for Cardiovascular And Chronic Care
Curtin University of Technology
38 Regent St, Chippendale
Sydney, NSW, 2008</address>
      <phone>+61 2 8399 7832</phone>
      <fax>+61 2 8399 7834</fax>
      <email>p.newton@curtin.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>